A Multiple Ascending Dose Study of Tadalafil to Assess the Pharmacokinetics and Safety in a Pediatric Population With Pulmonary Arterial Hypertension
Phase of Trial: Phase I/II
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Tadalafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 20 Jun 2019 Results published in the British Journal of Clinical Pharmacology
- 11 Apr 2019 Status changed from active, no longer recruiting to completed.
- 14 Jan 2019 Planned End Date changed from 1 May 2019 to 17 May 2019.